Serontin70 ml

Serontin is a succinimide-class anticonvulsant primarily used in the management of seizure disorders.

Established / FDA-approved use

• Absence (petit mal) seizures: Serontin is a first-line agent for the treatment of uncomplicated absence seizures in children and adults, used as monotherapy when absence seizures occur alone.

Adjunct / combination use

• In patients with mixed seizure disorders (absence seizures occurring together with other seizure types, such as generalized tonic-clonic seizures), Serontin is used together with other appropriate antiepileptic drugs, since it is not effective against tonic-clonic seizures on its own and may need to be combined with agents active against those seizure types.

Serontin is not indicated for seizure types other than absence seizures and should not be relied upon as sole therapy in patients with mixed seizure disorders.

Each dosage unit contains Ethosuximide as the active pharmaceutical ingredient.

Ethosuximide is commonly available as:

• Oral capsules (typically 250 mg per capsule)
• Oral solution/syrup (typically 250 mg per 5 mL)

Serontin is an anticonvulsant belonging to the succinimide chemical class. It has been used for decades as a standard treatment for absence seizures and works by a mechanism distinct from most other antiepileptic drugs.

Serontin is taken orally and is well absorbed from the gastrointestinal tract, making it suitable for long-term outpatient management of absence epilepsy.

Antiepileptic agent (Succinimide-class anticonvulsant)

Mechanism of action

Ethosuximide reduces low-threshold (T-type) calcium currents in thalamic neurons. Thalamic T-type calcium channels generate the pacemaker current that underlies the 3-Hz spike-and-wave discharges characteristic of absence seizures. By blocking these channels, Ethosuximide interrupts the abnormal thalamocortical oscillations responsible for absence (petit mal) seizures.

Pharmacokinetics

• Absorption: Well absorbed orally; peak plasma concentrations are reached within a few hours.
• Distribution: Widely distributed; minimal plasma protein binding.
• Metabolism: Extensively metabolized in the liver (largely via CYP3A4) to inactive metabolites.
• Elimination: Primarily renal excretion of metabolites; elimination half-life is long, supporting once- or twice-daily dosing.
• Therapeutic drug monitoring: Serum concentrations of Ethosuximide are sometimes monitored to guide dosing and confirm adherence, particularly when response is inadequate or toxicity is suspected.

Serontin may be taken with or without food; taking it with food can reduce stomach upset. Capsules should be swallowed whole with water. The oral solution should be measured accurately using a calibrated measuring device.

Take Serontin at the same time(s) each day to maintain steady blood levels. If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; do not double the dose. Do not stop Serontin suddenly without consulting a physician, as this can precipitate seizures.

Clinically significant interactions

• Valproic acid (valproate): Can alter (increase or decrease) plasma Serontin concentrations through complex metabolic interactions; concurrent use requires monitoring for altered seizure control or toxicity.
• Enzyme-inducing antiepileptics (phenytoin, carbamazepine, phenobarbital) and rifampin: May increase the metabolism of Serontin, lowering its plasma levels and reducing seizure control.
• Isoniazid: May inhibit the metabolism of Serontin, increasing its plasma levels and the risk of toxicity.
• Other CNS depressants (e.g., alcohol, sedatives, opioids): May have additive sedative effects when combined with Serontin.

Always inform the prescribing physician of all other medicines being taken before starting Serontin.

Common

• Gastrointestinal: nausea, vomiting, loss of appetite, abdominal pain, weight loss, diarrhea
• Central nervous system: drowsiness, dizziness, headache, lethargy, unsteady gait (ataxia), hiccups

Less common but serious

• Blood disorders (leukopenia, agranulocytosis, aplastic anemia, pancytopenia, eosinophilia) — see Precautions and Warnings for monitoring advice.
• Skin reactions including rash and, rarely, severe reactions such as Stevens-Johnson syndrome.
• Mood or behavior changes, including suicidal thoughts — see Precautions and Warnings.
• Lupus-like syndrome (rare).

Patients should seek prompt medical attention for unusual bruising/bleeding, sore throat with fever, persistent skin rash, or new/worsening mood changes while taking Serontin.

Pregnancy

Antiepileptic drugs as a class, including Serontin, carry teratogenic risk considerations. Serontin should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus. Uncontrolled seizures during pregnancy also carry risks to both mother and fetus, so Serontin should not be stopped abruptly without consulting a physician. Pregnant patients on Serontin should be managed by a specialist, with consideration of folic acid supplementation and prenatal monitoring.

Lactation

Serontin is excreted into breast milk in significant amounts. Breastfeeding while taking Serontin should be discussed with a physician, who will weigh the benefits of breastfeeding against the possibility of drowsiness or feeding difficulty in the infant, and monitor the infant accordingly.

• Blood dyscrasias: Serontin has rarely been associated with serious blood disorders (leukopenia, agranulocytosis, aplastic anemia, pancytopenia). Periodic blood counts are recommended during long-term therapy, and patients should promptly report fever, sore throat, unusual bruising, or bleeding.
• Suicidal thoughts/behavior: Antiepileptic drugs as a class, including Serontin, are associated with a small increased risk of suicidal ideation or behavior. Patients and caregivers should be alert to mood changes, anxiety, or unusual behavior and report these to a physician promptly.
• Mixed seizure disorders: In patients with absence seizures occurring together with other seizure types, Serontin used alone may unmask or increase the frequency of generalized tonic-clonic seizures; concomitant appropriate therapy may be required.
• Hepatic or renal impairment: Use Serontin with caution and closer clinical monitoring in patients with significant liver or kidney disease.
• Abrupt discontinuation: Do not stop Serontin suddenly, as this may precipitate absence status or seizure recurrence; dose reduction should be gradual and physician-supervised.

Overdose of Serontin may cause nausea, vomiting, drowsiness, confusion, unsteadiness, and in severe cases, significant central nervous system and respiratory depression, low blood pressure, or coma.

Suspected overdose of Serontin is a medical emergency: seek immediate medical attention or contact a poison control center/emergency services right away. Treatment is supportive and should be carried out in a hospital setting; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

Serontin is approved for use in children 3 years of age and older for absence seizures, with dosing individualized by age, weight, and response. Safety and efficacy in children under 3 years have not been established.

Elderly

Limited specific data are available in elderly patients; use Serontin with caution, starting at the lower end of the dosing range and monitoring closely, given the potential for age-related decline in hepatic/renal function.

Renal impairment

Use Serontin with caution and increased monitoring; no formal dose-adjustment guidelines are established.

Hepatic impairment

Use Serontin with caution and increased monitoring, since Serontin is extensively metabolized by the liver.

Duration of Serontin therapy is individualized and determined by the treating physician based on seizure control, EEG findings, and clinical course. Treatment is often continued long-term, and many patients require multi-year therapy. Any decision to reduce or stop Serontin should be made gradually and only under physician supervision, as abrupt discontinuation can trigger seizure recurrence.

Succinimide anticonvulsants; Antiepileptic drugs (AEDs)

Ethosuximide selectively blocks low-threshold (T-type) calcium channels in thalamic neurons. This reduces the thalamic pacemaker current that generates the abnormal 3-Hz spike-and-wave discharges seen on EEG during absence seizures, thereby suppressing the seizures without significantly affecting sodium channels or GABAergic transmission, distinguishing its mechanism from most other antiepileptic drugs.

C

Serontin is indicated for absence seizures in children 3 years of age and older. Dosing is weight- and age-based, typically starting at 250 mg once daily in children 3-6 years, and 250 mg twice daily in children over 6 years, with gradual titration by the physician to the lowest effective maintenance dose. Safety and efficacy of Serontin in children younger than 3 years have not been established, and blood counts and clinical monitoring are advised during long-term pediatric use.